J&J Buys 18% Stake in Biotech Firm Crucell
Editor's note: Biotech expert Adam Feuerstein will be the featured guest on TSC Live at noon EDT Tuesday, Sept. 29. Email your questions at tsclive@thestreet.com; tweet us on Twitter with hash tag #tsclive; leave a message on our Facebook page; or use the live show page's comments section. Bookmark the TSC Live page now.
NEW BRUNSWICK, N.J. (TheStreet) -- Johnson & Johnson (JNJ Quote) has purchased 14.6 million shares of Crucell(CRXL Quote), or 18% of the Dutch biotechnology company, for 301.8 million euros ($441 million) under a partnership to develop flu vaccines. J&J said the immediate focus of the collaboration will be to develop and commercialize a universal monoclonal antibody product (flu-mAb) for treating and preventing flu. The companies also will work to develop vaccines for other infectious and non-infectious diseases. The companies also have agreed to development milestones and royalty payments based on the successful development and commercialization of products. Under the flu-mAb collaboration, J&J's Ortho-McNeil-Janssen Pharmaceuticals division and Crucell will seek to develop a universal flu-mAb product targeting all influenza A strains, which cause seasonal flu and the current pandemic including H1N1 strains, and the bird flu strain. J&J said the transaction is expected to dilute 2009 adjusted earnings by 2 cents to 4 cents a share. -- Reported by Joseph Woelfel in New York . Follow TheStreet.com on Twitter and become a fan on Facebook.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,318.16 | 1,091.38 | 2,146.04 | 33.56 |
Oil *
77.53
|
|
DOWN
14.28
|
DOWN
3.52
|
DOWN
10.78
|
UP
0.07
|
10 Yr
3.36%
SPDR Gold
112.94
|
|
-0.14%
|
-0.32%
|
-0.50%
|
+0.21%
|
Data delayed 20 minutes |














